The Safety and Immunogenicity of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy Children
- 1 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 25 (7) , 615-622
- https://doi.org/10.1097/01.inf.0000220209.35074.0b
Abstract
This clinical trial was conducted to demonstrate that each of 3 consistency lots of a combined measles, mumps, rubella and varicella vaccine (MMRV) would be well tolerated, induce clinically acceptable and similar immune responses to each antigen and induce immune responses similar to measles, mumps and rubella vaccine (MMR) administered concomitantly with varicella vaccine (V). An additional objective was to evaluate the persistence of antibodies 1 year postvaccination. Study participants 12 to 23 months of age received a single injection of either one of 3 consistency lots of MMRV or MMR + V administered at separate injection sites. A total of 3,928 healthy children were enrolled at study sites in the United States and Canada. Immune responses to measles, mumps, rubella and varicella in children immunized with each of 3 lots of MMRV were similar and the combined response to all 3 lots was comparable to that of the control group. The 1-year antibody persistence rates for measles, mumps, rubella and varicella viruses were each greater than 95% and comparable among the recipients of the 3 consistency lots of MMRV and the control group. All vaccines were generally well tolerated during the 42 days after vaccination and the overall incidence of adverse experiences was comparable between recipients of MMRV and MMR + V. Rates of fever (temperature >or=38.9 degrees C oral equivalent or tactile) were greater in recipients of MMRV than in recipients of MMR + V (39.1% versus 33.1%, P = 0.001). Fevers were transient and there was no difference in the incidence of febrile seizures. MMRV was generally well tolerated and had comparable immunogenicity and overall safety profiles to MMR + V administered concomitantly. Long-term persistence of antibodies after receipt of MMRV is expected based on similar antibody titers against all 4 antigens 1 year postvaccination compared with recipients of MMR and V.Keywords
This publication has 13 references indexed in Scilit:
- Evaluation of a Quadrivalent Measles, Mumps, Rubella and Varicella Vaccine in Healthy ChildrenThe Pediatric Infectious Disease Journal, 2005
- Decline in Mortality Due to Varicella after Implementation of Varicella Vaccination in the United StatesNew England Journal of Medicine, 2005
- Ten year follow-up of healthy children who received one or two injections of varicella vaccineThe Pediatric Infectious Disease Journal, 2004
- Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infectionThe Pediatric Infectious Disease Journal, 2002
- Measles, Mumps, Rubella, and Varicella Combination Vaccine: Safety and Immunogenicity Alone and in Combination with Other Vaccines Given to ChildrenClinical Infectious Diseases, 1997
- Antibody assays suitable for assessing immune responses to live varicella vaccineVaccine, 1991
- Sensitive enzyme‐linked immunosorbent assay for antibody to varicella‐zoster virus using purified VZV glycoprotein antigenJournal of Medical Virology, 1990
- Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodiesJournal of Virological Methods, 1986
- Epidemiological Standardization of a Test for Susceptibility to MumpsThe Journal of Infectious Diseases, 1984
- Immunization with live attenuated measles virus vaccines: Five years' experienceArchiv für die gesamte Virusforschung, 1965